JPN | Nov 12, 2020

Japan’s Fujitsu, Mizuho, PeptiDream to form joint venture to develop COVID-19 treatments

/ Our Today

Reading Time: < 1 minute
A logo of Fujitsu Ltd. is pictured at the CEATEC JAPAN 2017 (Combined Exhibition of Advanced Technologies) at the Makuhari Messe in Chiba, Japan, October 2, 2017. (File Photo: REUTERS/Toru Hanai)

TOKYO (Reuters)

Fujitsu Ltd, Mizuho Financial Group Inc, and drugmaker PeptiDream Inc said on Thursday (November 12) they are forming a joint venture to develop treatments for COVID-19.

The new company, to be called PeptiAID Inc, will research and develop peptide therapeutics for the current SARS-CoV-2 virus and potential future coronavirus outbreaks, the companies said in a release.

The joint venture also includes Takenaka Corp and Kishida Chemical Co.

Mizuho Financial Group logo is seen at the company’s headquarters in Tokyo, Japan August 20, 2018. Picture taken August 20, 2018. (Photo: REUTERS/Toru Hanai)


What To Read Next